A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Cancer
- Gastric Cancer
- Ovarian Cancer
- Sarcoma
- Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
This is a single arm, open label, dose escalation clinical study to evaluate the safety and preliminary therapeutic efficacy of CCT303-406 cells in adult subjects with HER2 positive relapsed or refractory stage IV metastatic solid tumors. Subjects that meet inclusion criteria with positive biopsy HE...
This is a single arm, open label, dose escalation clinical study to evaluate the safety and preliminary therapeutic efficacy of CCT303-406 cells in adult subjects with HER2 positive relapsed or refractory stage IV metastatic solid tumors. Subjects that meet inclusion criteria with positive biopsy HER2 (IHC 3+ in ?50% tumor cells) will receive CCT303-406 according to the 3+3 dose escalation design.
Tracking Information
- NCT #
- NCT04511871
- Collaborators
- Shanghai Zhongshan Hospital
- Investigators
- Not Provided
Get Well Soon